A landmark study, the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial highlighted the importance of IL-1β as a key therapeutic target for cardiovascular diseases [66–68]. This evidence concerns the gene IL1B and cardiovascular disorder.